Skip to main content
. 2024 Mar 26;7(3):e243689. doi: 10.1001/jamanetworkopen.2024.3689

Table 2. Chromosomal and Pregnancy Outcomes by Nuchal Translucency Measurementa.

Outcome All pregnancies Nuchal translucency measurement, mm
<2.0 2.0 to <2.5 2.5 to <3.0 3.0 to <3.5 3.5 to <5.0 5.0 to <6.5 ≥6.5
No. of cytogenetic testing results 15 755 11 552 1875 653 421 602 287 365
Unknown result 217 (1.4) 180 (1.6) 22 (1.2) <6 (NA) <6 (NA) <6 (NA) <6 (NA) <6 (NA)
No chromosomal anomaly identified 12 106 (76.8) 9459 (81.9) 1397 (74.5) 450 (68.9) 241 (57.2) 341 (56.6) 112 (39.0) 106 (29.0)
Chromosomal anomaly 3432 (21.8) 1913 (16.6) 456 (24.3) 198 (30.3) 179 (42.5) 256 (42.5) 174 (60.6) 256 (70.1)
Identifiable on cfDNA screeningb,c 1690 (49.2) 543 (28.4) 241 (52.9) 154 (77.8) 149 (83.2) 215 (84.0) 153 (87.9) 235 (91.8)
Not identifiable on cfDNA screeningb,d 1742 (50.8) 1370 (71.6) 215 (47.1) 44 (22.2) 30 (16.8) 41 (16.0) 21 (12.1) 21 (8.2)
No. of cfDNA screening results for pregnancies without cytogenetic testing results 38 754 30 551 5310 1701 667 398 69 58
Unknown or uninformative result 495 (1.3) 404 (1.3) 58 (1.1) 14 (0.8) <6 (NA) 8 (2.0) <6 (NA) <6 (NA)
Low-risk result 38 041 (98.2) 30 071 (98.4) 5234 (98.6) 1674 (98.4) 645 (96.7) 354 (88.9) 44 (63.8) 19 (32.8)
High-risk result 218 (0.6) 76 (0.2) 18 (0.3) 13 (0.8) 18 (2.7) 36 (9.0) 21 (30.4) 36 (62.1)
No. of pregnancy outcomes with neither cytogenetic testing nor cfDNA screening results 359 759 317 704 36 034 5120 701 88 48 64
Lost to follow-up 10 761 (3.0) 9281 (2.9) 1132 (3.1) 181 (3.5) 42 (6.0) 38 (43.2) 39 (81.3) 48 (75.0)
Live birth 347 190 (96.5) 306 838 (96.6) 34 727 (96.4) 4901 (95.7) 655 (93.4) 49 (55.7) 7 (14.6) 13 (20.3)
Clinical findings at birthe 15 552 (4.5) 13 919 (4.5) 1391 (4.0) 203 (4.1) 33 (5.0) <6 (NA) <6 (NA) <6 (NA)
Pregnancy loss, termination, or stillbirth 1808 (0.5) 1585 (0.5) 175 (0.5) 38 (0.7) <6 (NA) <6 (NA) <6 (NA) <6 (NA)
No. of pregnancies with chromosomal anomalies 414 268 359 807 43 219 7474 1789 1088 404 487
No chromosomal anomaly identifiedf 382 478 (92.3) 332 945 (92.5) 40 046 (92.7) 6846 (91.6) 1522 (85.1) 771 (70.9) 179 (44.3) 169 (34.7)
Chromosomal anomalyg 3432 (0.8) 1913 (0.5) 456 (1.1) 198 (2.6) 179 (10.0) 256 (23.5) 174 (43.1) 256 (52.6)
Excluded 28 358 (6.8) 24 949 (6.9) 2717 (6.3) 430 (5.8) 88 (4.9) 61 (5.6) 51 (12.6) 62 (12.7)
Lost to follow-up 10 761 (2.6) 9281 (2.6) 1132 (2.6) 181 (2.4) 42 (2.3) 38 (3.5) 39 (9.7) 48 (9.9)
Excluded for other reasonh 17 597 (4.2) 15 668 (4.4) 1585 (3.7) 249 (3.3) 46 (2.6) 23 (2.1) 12 (3.0) 14 (2.9)

Abbreviations: cfDNA, cell-free DNA; NA, not applicable.

a

Unless otherwise indicated, data are expressed as No. (%) of patients.

b

Includes those with choromosomal anomaly identified.

c

Includes trisomies 21, 18, and 13 and sex chromosome aneuploidies.

d

Includes all other chromosomal anomalies, including other autosomal aneuploidies, mosaic aneuploidies, copy number variants. A detailed list of all chromosomal anomalies is available in eTable 2 in Supplement 1.

e

Includes any congenital structural anomaly identified among live births.

f

Indicates normal cytogenetic results or no cytogenetic results but low risk cfDNA results or no follow-up testing results but documented live birth with no clinical findings on examination.

g

Based on cytogenetic testing results.

h

Includes pregnancy loss, stillbirth, termination, live birth with clinical findings, or a high-risk cfDNA screening result.